CIA
IBRX icon

Capital Investment Advisors’s ImmunityBio IBRX Stock Holding History

Capital Investment Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121K Sell
13,789
-7,948
-37% -$60.2K ﹤0.01% 775
2026
Q1 		$167K Buy
+21,737
New +$149K ﹤0.01% 727

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Investment Advisors's IBRX Position: Q2 2026 in Review

Capital Investment Advisors reduced its ImmunityBio (IBRX) stake by 37% in Q2 2026, selling an estimated $60.2K and leaving 13,789 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #775.

Capital Investment Advisors first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $167K in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Capital Investment Advisors held 13,789 shares of ImmunityBio worth $121K as of Q2 2026.
  • Capital Investment Advisors sold 7,948 ImmunityBio shares in Q2 2026, an estimated $60.2K.
  • ImmunityBio made up ﹤0.01% of Capital Investment Advisors's portfolio in Q2 2026, its #775 holding.
  • Capital Investment Advisors first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • Capital Investment Advisors's ImmunityBio position peaked at $167K in Q1 2026.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Capital Investment Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.